Literature DB >> 29514506

Neighbourhood Material and Social Deprivation and Exposure to Antidepressant Drug Treatment: A Cohort Study Using Administrative Data.

Sophie Lauzier1,2, Hichem Kadachi3, Jocelyne Moisan1,2, Alain Vanasse4,5, Alain Lesage6, Marie-Josée Fleury7,8, Jean-Pierre Grégoire1,2.   

Abstract

OBJECTIVE: To assess whether neighbourhood deprivation is associated with exposure to an antidepressant drug treatment (ADT) and its quality among individuals diagnosed with unipolar depression and insured by the Quebec public drug plan.
METHOD: We conducted an administrative database cohort study of adults covered by the Quebec public drug plan who were diagnosed with a new episode of unipolar depression. We assessed material and social deprivation using an area-based index. We considered exposure to an ADT as having ≥1 claim for an ADT within the 365 days following depression diagnosis. Among those exposed to ADT, ADT quality was assessed with 3 indicators: first-line recommended ADT, persistence with the ADT, and compliance with the ADT. Generalized linear models were used to estimate adjusted prevalence ratios (aPR) and 95% confidence intervals (95% CI).
RESULTS: Of 100,432 individuals with unipolar depression, 65,436 (65%) were exposed to an ADT in the year following the diagnosis. Individuals living in the most materially deprived areas were slightly more likely to be exposed to an ADT than those living in the least deprived areas (aPR, 1.04; 95% CI, 1.03 to 1.06). The likelihoods of being exposed to a first-line ADT, persisting for the minimum recommended duration and complying with the ADT were independent of the deprivation levels.
CONCLUSIONS: Neighbourhood deprivation was not associated with ADT quality among individuals insured by the Quebec public drug plan. It might be partly attributable to the public drug plan whose goal is to provide equitable access to prescription drugs regardless of income.

Entities:  

Keywords:  administrative databases; antidepressant agents; cohort studies; depression; drug prescriptions; medication adherence; residence characteristics; socioeconomic factors

Mesh:

Substances:

Year:  2018        PMID: 29514506      PMCID: PMC6187437          DOI: 10.1177/0706743718760290

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  52 in total

Review 1.  Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments.

Authors:  S H Kennedy; R W Lam; N L Cohen; A V Ravindran
Journal:  Can J Psychiatry       Date:  2001-06       Impact factor: 4.356

2.  Predicting persistence to antidepressant treatment in administrative claims data: Considering the influence of refill delays and prior persistence on other medications.

Authors:  Greta A Bushnell; Til Stürmer; Alice White; Virginia Pate; Sonja A Swanson; Deborah Azrael; Matthew Miller
Journal:  J Affect Disord       Date:  2016-02-09       Impact factor: 4.839

Review 3.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.

Authors:  Sidney H Kennedy; Raymond W Lam; Roger S McIntyre; S Valérie Tourjman; Venkat Bhat; Pierre Blier; Mehrul Hasnain; Fabrice Jollant; Anthony J Levitt; Glenda M MacQueen; Shane J McInerney; Diane McIntosh; Roumen V Milev; Daniel J Müller; Sagar V Parikh; Norma L Pearson; Arun V Ravindran; Rudolf Uher
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

4.  Social inequalities in early antidepressant discontinuation.

Authors:  Aurélie Bocquier; Sébastien Cortaredona; Hélène Verdoux; Ludovic Casanova; Vincent Sciortino; Stève Nauleau; Pierre Verger
Journal:  Psychiatr Serv       Date:  2014-05-01       Impact factor: 3.084

5.  Using administrative databases in the surveillance of depressive disorders--case definitions.

Authors:  Reza Alaghehbandan; Don Macdonald; Brendan Barrett; Kayla Collins; Yue Chen
Journal:  Popul Health Manag       Date:  2012-07-12       Impact factor: 2.459

6.  Social inequalities in antidepressant treatment and mortality: a longitudinal register study.

Authors:  Mika Kivimäki; David Gunnell; Debbie A Lawlor; George Davey Smith; Jaana Pentti; Marianna Virtanen; Marko Elovainio; Timo Klaukka; Jussi Vahtera
Journal:  Psychol Med       Date:  2006-11-23       Impact factor: 7.723

7.  Physician race and treatment preferences for depression, anxiety, and medically unexplained symptoms.

Authors:  Ryan E Lawrence; Kenneth A Rasinski; John D Yoon; Farr A Curlin
Journal:  Ethn Health       Date:  2014-05-29       Impact factor: 2.772

8.  Socioeconomic differences in antidepressant use in the PATH Through Life Study: evidence of health inequalities, prescribing bias, or an effective social safety net?

Authors:  Peter Butterworth; Sarah C Olesen; Liana S Leach
Journal:  J Affect Disord       Date:  2013-02-08       Impact factor: 4.839

9.  Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy.

Authors:  Raymond W Lam; Sidney H Kennedy; Sophie Grigoriadis; Roger S McIntyre; Roumen Milev; Rajamannar Ramasubbu; Sagar V Parikh; Scott B Patten; Arun V Ravindran
Journal:  J Affect Disord       Date:  2009-08-11       Impact factor: 4.839

10.  Sociodemographic and clinical predictors of compliance with antidepressants for depressive disorders: systematic review of observational studies.

Authors:  Amado Rivero-Santana; Lilisbeth Perestelo-Perez; Jeanette Pérez-Ramos; Pedro Serrano-Aguilar; Carlos De Las Cuevas
Journal:  Patient Prefer Adherence       Date:  2013-03-03       Impact factor: 2.711

View more
  1 in total

1.  Do people living in disadvantaged circumstances receive different mental health treatments than those from less disadvantaged backgrounds?

Authors:  Clarissa Giebel; Rhiannon Corcoran; Mark Goodall; Niall Campbell; Mark Gabbay; Konstantinos Daras; Ben Barr; Tim Wilson; Cecil Kullu
Journal:  BMC Public Health       Date:  2020-05-11       Impact factor: 3.295

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.